GT Biopharma, Inc.

The momentum for this stock is not very good. GT Biopharma, Inc. is not very popular among insiders. GT Biopharma, Inc. is a mediocre stock to choose.

News

GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update

Ticker Report GT Biopharma, Inc. (NASDAQ:GTBP - Get Free Report) saw a significant increase in short interest in the month of August. As of August 15th, there was short interest totalling 19,300 shares, an...\n more…

GT Biopharma GAAP EPS of -$2.17

SeekingAlpha.com: All News GT Biopharma (GTBP) reports Q2 GAAP EPS of -$2.17. Cash of $9.2 million as of June 30, 2024 expected to fund operations into 2025.\n more…

GTBP Stock Earnings: GT Biopharma Reported Results for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nGT Biopharma just reported results for the second quarter of 2024.\nThe post GTBP Stock Earnings: GT Biopharma Reported Results for Q2...\n more…

GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Globe Newswire GTB-3650 TriKE Phase 1 trial initiation expected in 2H 2024; initial clinical data expected in 1H 2025GTB-5550 TriKE IND submission for treatment of B7H3 positive solid tumors expected in 1H...\n more…

GT Biopharma announces FDA clearance of IND application for GTB-3650

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

Globe Newswire GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025GTB-5550 TriKE IND submission for treatment of B7H3 positive solid tumors expected in Q1 2025GTB-5550...\n more…